Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14083591 | 0.91 | TRPV1 (0.45) | TRPV1NTRK1MEN1KMT2ASLC16A3 | |
| SCHEMBL14083593 | 0.87 | TRPV1 (0.52) | TRPV1NTRK1MEN1KMT2ATDP1 | |
| SCHEMBL14083582 | 0.84 | TRPV1 (0.49) | TRPV1NTRK1MEN1KMT2AGRM4 | |
| SCHEMBL14108062 | 0.84 | HDAC1 (0.52) | TRPV1NTRK1MEN1KMT2AGRM4 | |
| SCHEMBL14083621 | 0.84 | RAB9A (0.53) | TRPV1MEN1KMT2ATDP1SCN5A | |
| SCHEMBL14083598 | 0.83 | GAA (0.52) | TRPV1MEN1KMT2AGRM4SCN5A | |
| SCHEMBL14083496 | 0.83 | TRPV1 (0.55) | TRPV1MEN1KMT2ASLC16A3SCN5A | |
| SCHEMBL14083940 | 0.82 | HIF1A (0.51) | TRPV1SLC16A3TDP1SCN5ASCN9A | |
| SCHEMBL14082758 | 0.81 | P2RX7 (0.59) | MEN1KMT2ATDP1 | |
| SCHEMBL14083583 | 0.81 | HDAC1 (0.51) | TRPV1NTRK1MEN1KMT2AGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885MET 3593/4885NTRK1 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.